BioNTech Hosts Second AI Day with InstaDeep

TL;DR

BioNTech's AI Day 2.0 is here, showcasing AI-driven drug development with InstaDeep.

AI Summary

On October 1, 2025, BioNTech SE, in collaboration with its AI subsidiary InstaDeep Ltd., held its second AI Day. This event showcased advancements and future directions in the application of artificial intelligence within BioNTech's operations and research.

Why It Matters

This event highlights BioNTech's strategic focus on integrating AI into its drug discovery and development processes, potentially accelerating innovation and improving therapeutic outcomes.

Risk Assessment

Risk Level: low — The filing is an informational report about an event and does not contain material financial changes or new risks.

Key Players & Entities

• BioNTech SE (company) — Registrant and presenter
• InstaDeep Ltd. (company) — AI subsidiary and collaborator
• October 1, 2025 (date) — Date of the AI Day event

FAQ

From the Filing

0001776985-25-000061.txt : 20251001 0001776985-25-000061.hdr.sgml : 20251001 20251001090532 ACCESSION NUMBER: 0001776985-25-000061 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 131 CONFORMED PERIOD OF REPORT: 20251001 FILED AS OF DATE: 20251001 DATE AS OF CHANGE: 20251001 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251362696 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kaidaypresentation1o.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On October 1, 2025, BioNTech SE (“BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd., hosted its second AI Day, an edition of BioNTech’s “Innovation Series”, providing an overview of BioNTech’s AI strategy and capabilities and the application of AI in BioNTech’s pipeline and internal processes. The presentation is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Ramon Zapata-Gomez By: /s/ Dr. Sierk Poetting Name: Ramon Zapata-Gomez Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: October 1, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Presentation EX-99.1 2 exhibit991biontechaiday-.htm EX-99.1 exhibit991biontechaiday- AI Day © 2025 BioNTech SE & InstaDeep Ltd. October 1, 2025 Exhibit 99.1 This slide presentation includes forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control; and which could cause actual results to differ materially from those expressed or im